Abstract:Background: Familial hypercholesterolemia (FH) is a common monogenic autosomal dominant disorder, primarily mainly caused by pathogenic mutations in the low-density lipoprotein receptor (LDLR) gene. Through phenotypic-genetic linkage analysis, two LDLR pathogenic mutations were identified in FH families: c.G1027A (p.Gly343Ser) and c.G1879A (p.Ala627Thr). Materials and methods: Whole exome sequencing was conducted on the proband with familial hypercholesterolemia to identify the target gene and screen for potential pathogenic mutations. The suspicious responsible mutation sites in 14 family members were analyzed using Sanger sequencing to assess genotype-phenotype correlations. Mutant and wild type plasmids were constructed and transfected into HEK293T cells to evaluate LDLR mRNA and protein expression. In parallel, bioinformatics tools were employed to predict structural and functional changes in the mutant LDLR. Results: Immunofluorescence analysis revealed no significant difference in the intracellular localization of the p.Gly343Ser mutation, whereas protein expression of the p.Ala627Thr mutation was decreased and predominantly localized in the cytoplasm. Western blotting has showed that protein expression levels of the mutant variants were markedly declined in both cell lysates and supernatants. Enzyme linked immunosorbent assay has demonstrated that LDLR protein levels in the supernatant of cell culture medium was not significant different from those of the wild-type group. However, LDLR protein levels in the cell lysate of both the Gly343Ser and Ala627Thr variants groups were significantly lower than those in the wild-type group. Bioinformatic predictions further suggested that these mutations may affect post-translational modifications of the protein, providing additional insight into the mechanisms underlying the observed reduction in protein expression. Conclusions: In this study, we identified two heterozygous pathogenic variants in the LDLR gene, c.G1027A (p.Gly343Ser) and c.G1879A (p.Ala627Thr), in a family with familial hypercholesterolemia. We also conducted preliminary investigations into the mechanisms by which these mutations contribute to disease pathology.

Novel Mutations of Low-Density Lipoprotein Receptor Gene in China Patients with Familial Hypercholesterolemia.

GW24-e3589 A novel mutation 1587_1588 del2 of the low-density lipoprotein receptor gene associated with familial hypercholesterolemia in a Chinese family

Identification of a Novel Mutation at the Point of Low Density Lipoprotein Receptor Gene from a Subject with Familial Hypercholesterolemia

Identification of Ldlr Mutations in Two Chinese Pedigrees with Familial Hypercholesterolemia

Novel LDLR variants affecting low density lipoprotein metabolism identified in familial hypercholesterolemia

Identification of One Novel Mutation of the Low Density Lipoprotein Receptor Gene in Chinese Patients with Familial Hypercholesterolemia

Gene Sequencing Research of Three Familial Hypercholesterolemia Families

Genetic Basis of Index Patients with Familial Hypercholesterolemia in Chinese Population: Mutation Spectrum and Genotype-Phenotype Correlation

Genetic analysis in the patients with familial hypercholesterolemia

Analysis of low-density lipoprotein receptor gene mutations in a family with familial hypercholesterolemia

Mutation Analysis of Low-Density Lipoprotein Receptor Gene in 3 Patients with Familial Hypercholesterolemia in Two Generations

Screening and verifying the mutations in the LDLR and APOB genes in a Chinese family with familial hypercholesterolemia

Identification and Functional Characterization of a Low-Density Lipoprotein Receptor Gene Pathogenic Variant in Familial Hypercholesterolemia

Genetic Analysis in a Taiwanese Cohort of 750 Index Patients with Clinically Diagnosed Familial Hypercholesterolemia.

Genetic Analysis in a Compound Heterozygote Family with Familial Hypercholesterolemia.

LDLR c.89_92dup: a novel frameshift variation in familial hypercholesterolemia

Familial Hypercholesterolemia: Current Limitations and Future Breakthroughs

Clinical observations and treatment of pediatric homozygous familial hypercholesterolemia due to a low-density lipoprotein receptor defect.

Next-generation Sequencing Verified by Multiplex Ligation-Dependent Probe Amplification to Detect a New Copy Number Variations in a Child with Heterozygous Familial Hypercholesterolemia

Hyperlipidemia patients carrying LDLR splicing mutation c.1187-2A>G respond favorably to rosuvastatin and PCSK9 inhibitor evolocumab

Prevalence and patient characteristics of familial hypercholesterolemia in a Chinese population aged 35–75 years: Results from China PEACE Million Persons Project